



## Umbilical Cord Blood Transplantation after Reduced-Intensity Conditioning for Elderly Patients with Hematologic Diseases

Naoyuki Uchida, Atsushi Wake, Shinsuke Takagi, Hisashi Yamamoto, Daisuke Kato, Yoshiko Matsubashi, Tomoko Matsumura, Sachiko Seo, Naofumi Matsuno, Kazuhiro Masuoka, Eiji Kusumi, Koichiro Yuji, Shigesaburo Miyakoshi, Michio Matsuzaki, Akiko Yoneyama, Shuichi Taniguchi

Department of Hematology, Toranomon Hospital, Tokyo, Japan

Correspondence and reprint requests: Naoyuki Uchida, MD, 2-2-2 Toranomon, Minato-Ku, Tokyo 105-8470, Japan (e-mail: nuchida@toranomon.gr.jp).

Received October 13, 2007; accepted March 11, 2008

### ABSTRACT

Although allogeneic hematopoietic stem cell transplantation is a potentially curative approach for advanced hematologic diseases, its application to elderly people is limited because of their comorbid physical conditions and lower chance of finding suitable related donors. Umbilical cord blood transplantation with reduced-intensity pretransplant conditioning (RI-UCBT) is 1 way to avoid these obstacles. We analyzed elderly patients aged 55 years and older with hematologic diseases who underwent RI-UCBT at our institute to assess feasibility and effectiveness of this treatment approach. Among the 70 patients included, 50 died, 74% of them from non-relapse causes. Infection was the primary cause of death. Estimated overall survival and progression-free survival at 2 years were both 23%. In multivariate analyses, standard-risk diseases, age younger than 61 years, grade 0-II acute graft-versus-host disease, and the absence of preengraftment immune reaction were significantly associated with better overall survival. RI-UCBT is a potentially curative and applicable approach for elderly patients. Higher mortality, especially from nonrelapse causes, is the biggest problem to be solved to increase the feasibility of this approach.

© 2008 American Society for Blood and Marrow Transplantation

### KEY WORDS

Cord blood transplantation • Reduced intensity • Elderly patients • Hematologic diseases

### INTRODUCTION

Although morbidity associated with hematologic malignant diseases in elderly patients is higher than that in younger patients [1], elderly patients are less likely to be candidates for allogeneic stem cell transplantation, because of the fact that they are more likely to have comorbid organ conditions, either clinically or subclinically, which result in a higher rate of procedure-related mortality [2], and that they are less likely to have HLA-matched related donors available, as siblings also tend to be elderly.

The development of reduced-intensity conditioning (RIC) for transplants, which results in less toxicity and depends largely on graft-versus-tumor effects rather than high-dose therapy to eliminate malignant cells, has been shown to allow elderly patients to undergo allogeneic transplants [3-5]. The use of umbilical

cord blood transplantation (UCBT) has been increasing because of the potential advantage of rapid availability and the lower risk of graft-versus-host disease (GVHD), thus permitting less stringent HLA matching [6,7]. The outcome of UCBT has been reported to be similar to unrelated bone marrow in the myeloablative setting [8-10]. UCBT with reduced-intensity pretransplant conditioning (RI-UCBT) for adults, mostly younger than 55 years old, has been increasingly reported, and has been shown to be applicable even in patients with a relatively low number of nucleated cells for their body weight [11-16]. However, little information has been available on whether elderly patients can tolerate slower engraftment, more infectious complications [17], and the unique preengraftment immune reaction (PIR) associated with UCBT [18,19]. PIR has been described by us and others [18,19], characterized

by the symptoms induced possibly by hypercytokinemia, which sometimes cause severe organ damage and fatal outcome. We therefore retrospectively evaluated the use of the RI-UCBT in patients aged 55 and older by analyzing engraftment, nonrelapse mortality (NRM), GVHD, progression-free (PFS), and overall survival (OS) to address the feasibility and effectiveness of this method in older patients.

## PATIENTS, MATERIALS, AND METHODS

### Patients

This study included patients aged 55 and older who underwent RI-UCBT at our institute from July 18, 2002 through October 28, 2005. Patients were eligible for this study if they had any hematologic malignancies at high risk for relapse or severe aplastic anemia (AA) refractory to standard immunosuppressive therapy, as well as if they were unable to find suitable related or unrelated bone marrow (BM)/peripheral blood (PB) donors within reasonable time periods relative to their disease conditions. Patients with acute leukemia could be at first remission but at high risk for relapse because of adverse cytogenetic abnormalities, have a prior hematologic disorder, or be at any status beyond first remission. Patients with myelodysplastic syndrome (MDS) had to be refractory anemia with excess of blasts or chronic myelomonocytic leukemia, or have refractory anemia with transfusion dependency and/or severe neutropenia. Patients with chronic myeloid leukemia (CML) had to be beyond the first chronic phase. Lymphoma patients had to be beyond the first remission except those with acute or lymphoma type adult T cell leukemia. Patients who had end-stage organ dysfunction (DLCO <30% predicted or LVEF <35%), or active serious infection at the time of transplantation were not eligible. All patients gave written informed consent, and the study was approved by the appropriate institutional review boards.

### Donor Selection

UCB units were obtained from Japanese Cord Blood Bank Network. HLA-A and HLA-B antigens were identified by serologic typing. HLA-DRB1 alleles were determined by high-resolution molecular typing using polymerase chain reaction (PCR) sequence-specific primers. UCB grafts had at least 4 of 6 HLA-A, B antigens, and DRB1 alleles that were matched to the recipient and had a cryopreserved cell dose of at least  $1.8 \times 10^7$  nucleated cells per kg of recipient body weight. The median total nucleated cell number and median CD34<sup>+</sup> cell number were 2.8 (range: 1.8–5.2)  $\times 10^7$ /kg and 0.84 (0.11–3.28)  $\times 10^5$ /kg, respectively.

### Patient Characteristics

Seventy consecutive patients were included in this study. Their characteristics are shown in Table 1.

Table 1. Patient and Donor Umbilical Cord Blood Characteristics

Characteristic	No. (%) of Patients
<b>Sex</b>	
Male	45 (64)
Female	25 (36)
<b>Age (years)</b>	
Median (range)	61 (55-79)
<b>Age distribution (years)</b>	
55 to 59	31 (44)
60 to 64	16 (23)
65 to 69	17 (24)
At least 70	6 (9)
<b>Diagnosis</b>	
AML	28 (40)
MDS	3 (4)
CML	4 (6)
ALL	11 (16)
NHL	8 (11)
ATL	12 (17)
MM	1 (1)
PCL	1 (1)
AA	2 (3)
<b>HCT-CI</b>	
0	24 (34)
1	25 (36)
2	11 (16)
3 or greater	10 (14)
<b>History of prior chemotherapy</b>	
Yes	59 (84)
No	11 (16)
<b>History of prior documented infections</b>	
Yes	15 (21)
No	55 (79)
<b>Disease status</b>	
Standard risk	15 (21)
High risk	55 (79)
<b>Conditioning regimen</b>	
Flu/Mel/TBI	65 (93)
Flu/Bu/TBI	4 (6)
Others	1 (1)
<b>GVHD prophylaxis</b>	
Cyclosporine A alone	37 (53)
Tacrolimus alone	33 (47)
<b>HLA disparity to UCB</b>	
5/6	9 (13)
4/6	61 (87)
<b>Sex mismatch to UCB</b>	
Yes	51 (73)
No	19 (27)

AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; ATL, adult T cell leukemia; MM, multiple myeloma; PCL, plasma cell leukemia; AA, aplastic anemia; Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; Bu, busulfan; UCB, umbilical cord blood; HCT-CI, hematopoietic cell transplantation-specific comorbidity index.

Of these 70 patients, 25 were women and 45 were men. Their median age was 61 years (range: 55-79 years). The patients' diagnoses included acute myeloid leukemia (AML; n = 28), acute lymphoblastic leukemia (ALL; n = 11), MDS (n = 3), CML (n = 4), non-Hodgkin lymphoma (NHL; n = 8), adult T cell

leukemia (n = 12), plasma cell leukemia (n = 1), multiple myeloma (n = 1), and AA (n = 2). Three patients had previous autologous hematopoietic cell transplantation. For disease status, those with hematologic malignancies in first or second complete remission at the time of transplant, those in the chronic phase or accelerated phase of CML, those with refractory anemia of MDS, and those with nonmalignant diseases were defined as being at standard risk (n = 15), whereas those in other situations were defined as being at high risk (n = 55). Patients were assessed for their comorbidity by the previously reported scoring system [20].

#### Conditioning Regimens and Postgrafting Immunosuppression

Pretransplant conditioning varied, and was determined by each attending physician according to the patient's disease, disease status, and history of prior therapy. Sixty-five patients underwent conditioning regimens with 125-180 mg/m<sup>2</sup> of fludarabine (Flu; 25 mg/m<sup>2</sup> for 5 days or 30 mg/m<sup>2</sup> for 6 days), along with 80 mg/m<sup>2</sup> of melphalan (Mel; 40 mg/m<sup>2</sup> for 2 days) and total-body irradiation (TBI) at a total dose of 4 Gy for 63 and 2 Gy for 2. Four patients in relatively poor performance status were conditioned with busulfan to avoid severe gastrointestinal tract toxicity induced by the use of Mel. One patient underwent a conditioning regimen with thiopeta (5 mg/kg for 2 days) in addition to 125 mg/m<sup>2</sup> of Flu and 80 mg/m<sup>2</sup> of Mel, because of the urgent transplant schedule that did not allow access to TBI. Valproate sodium (300 mg/day) was administered to all patients who received Bu. Immunosuppressive therapy with cyclosporine A (CsA, 3 mg/kg continuous infusion, aiming for a serum concentration of 250-400 ng/mL) or tacrolimus (Tac, 0.03 mg/kg continuous infusion, aiming for 12-17 ng/mL) was started on day -1. CsA was used for patients in the early phase of this study, and, based on our early experience of high early mortality related to PIR in the patients with CsA prophylaxis, Tac was subsequently used to substitute for CsA.

#### Supportive Care

Prophylactic antibiotics, including fluorquinolone, fluconazole, and acyclovir, were used routinely. Patients received ganciclovir or foscarnet for any sign of a cytomegalovirus reactivation, such as isolation of CMV or detection of viral proteins (pp65) or nucleic acid in any body fluid or tissue specimen. *Pneumocystis jirovecii* prophylaxis included trimethoprim-sulfamethoxazole as first-line therapy.

#### Definition of Engraftment, Preengraftment Immune Reaction, and End Points

OS and PFS were computed from the date of transplantation. Engraftment was defined as absolute neutrophil count  $>0.5 \times 10^9/L$  for 3 consecutive

days. Chimerism was assessed using fluorescent in situ hybridization in sex-mismatched donor-recipient pairs. In sex-mismatched pairs, PCR for variable number of tandem repeats was used with donor cells detected at a sensitivity of 10%. Whole blood or BM cells were assessed at the time of granulocyte engraftment. PIR was characterized by the presence of at least 2 of the following symptoms with no direct consequences of infection or adverse effects of medication 6 or more days before engraftment, as described previously [12,18]: a high fever ( $>38.5^\circ C$ ), skin eruptions, diarrhea, jaundice (serum levels of total bilirubin  $>2.0$  mg/dL), or body weight gain  $>10\%$  of baseline. NRM was defined as death in the absence of disease progression. Deaths occurring after disease progression were categorized as relapse regardless of the cause of death. Infection was considered the cause of death when bacterial, viral, or fungal infection was determined to be the proximate cause of death in patients who had not relapsed. Patients underwent BM aspiration at the time of engraftment or if clinically indicated. Relapse for AML, ALL, CML, or MDS was determined by flow cytometric, morphologic, or cytogenetic evidence of malignant or dysplastic cells with clonal markers similar to those observed before transplantation. Relapse for NHL was defined as progressive adenopathy or BM involvement. Acute and chronic GVHD (aGVHD, cGVHD) were defined and graded by standard criteria [21]. The following factors were considered potential predictors of outcomes: recipient's age, disease risk (standard versus high), ECOG performance status, HCT-specific comorbidity index score, history of prior chemotherapy (all cytoreductive chemotherapy excluding hydroxyurea and imatinib mesylate), history of prior documented infections (infectious episode with positive culture results for bacterial or yeast infections, and at least probable diagnosis of mold infection by EORTC/NIH-MSG criteria [22]), number of total nucleated cord blood cells, number of CD34<sup>+</sup> cells, HLA disparity, conditioning regimen, GVHD prophylaxis, grade of aGVHD, and the presence or absence of PIR.

#### Statistical Methods

OS was calculated from the day of transplantation until death from any cause or last follow-up. Disease-free survival (DFS) was calculated from the day of transplantation until relapse or death from any cause or last follow-up. The probabilities of survival and DFS were estimated and plotted using the Kaplan-Meier method [23]. Relapse and NRM rates were estimated using cumulative incidence analysis and were considered competing risks [24]. Similarly, in the analysis of GVHD rates, death because of other causes or relapse leading to early withdrawal of immune suppression were considered competing risks. The effect

of various patient and disease categorical variables on survival probabilities was studied with the log-rank test. A Cox proportional hazard model with limited variables because of small sample was used to determine the significance of multiple variables in determining these outcomes. Cumulative incidence curves were drawn using Gray's method [25].

## RESULTS

### Engraftment

Ten of the 70 patients were not evaluable for donor engraftment because of early death (before 28 days posttransplant) from disease progression ( $n = 1$ ), infection ( $n = 7$ ), and complications of central nervous system ( $n = 2$ ). Of the 60 evaluable patients, the cumulative incidence of primary donor engraftment was 92% at a median of 18 days after transplantation (range: 11–53 days). Platelet recovery  $>20 \times 10^9/L$  was observed in 38 patients (63%), at a median of 35 days (range: 25–95 days). All patients required transfusions of platelets and red blood cells. Recovery of neutrophil counts  $>0.5 \times 10^9/L$  did not occur in 5 patients who survived beyond 28 days posttransplant; these patients were classified as primary graft failures. Two of these patients received secondary RI-UCBT and died of infection. The remaining 3 patients died of infection. All engrafting patients without BM relapse were complete donor chimeras beyond 1 month after transplantation (data not shown). Remarkably, all 3 evaluated patients of 10 who died before day 28 showed complete donor chimerism (94%, 100%, and 94.6% on days 12, 15, and 20 posttransplant, respectively).

### PIR and GVHD

Forty-three patients experienced clinical symptoms defined as PIR, as described previously [12,18]. Patients who received Tac as GVHD prophylaxis tended to have a lower chance of experiencing PIR compared with those who received CsA, although differences were not statistically significant (53% versus 72%, respectively;  $P = .1$ ).

Among 54 evaluable patients, 33 patients (61%) developed aGVHD of grade II or higher, including 23 patients (43%) who developed that of grade III or IV. Of the 30 patients who survived longer than 100 days posttransplant, 12 (40%) developed cGVHD, including 7 with limited and 5 with extensive form (Table 2).

### Survival, Disease Progression, and NRM

At the time of analysis, 20 of 70 patients survived a median of 512 days (range: 103–1213 days) after transplantation. The Kaplan-Meier estimates of OS and PFS at 2 years were both 23% (Figure 1). The median OS time was 114 days (range: 7–1213 days), and the median PFS time was 92 days (range: 7–1213 days).

**Table 2.** The Incidence and Severity of Graft-versus-Host Disease (GVHD)


	Patients (n = 54)	
	No.	(%)
<b>Acute GVHD</b>	<b>45</b>	<b>(83)</b>
Grade II-IV	33	(61)
Grade III-IV	23	(43)
	Patients (n = 30)	
	No.	(%)
<b>Chronic GVHD</b>	<b>12</b>	<b>(40)</b>
Limited	7	(23)
Extensive	5	(17)

Eighteen patients (26%) showed progression of the underlying disease at a median of 134 days (range: 13–785 days) after transplantation, and 15 of these patients died of their disease.

Thirty-seven patients died of nonrelapse causes (Table 3). Nineteen of them were from infections, which was the leading cause of NRM. Among 33 deaths observed before day 100 posttransplant, 30 were from nonrelapse causes and 3 from disease progression. The cumulative incidences curves of NRM and disease progression are shown in Figure 2.

### Factors Contributing to OS and NRM

In univariate analyses, survival was associated with recipient's age ( $P = .01$ ), disease risk ( $P < .01$ ), aGVHD ( $P < .01$ ), and PIR ( $P < .01$ ), with favorable outcomes in younger recipients ( $<61$  years), those with standard risk, those with lower grade aGVHD (grade 0-II), and those without PIR (Figure 3A-D). Potential risk factors such as ECOG performance status, HCT-specific comorbidity index score, history of prior documented infection, history of prior chemotherapy, HLA disparity,



**Figure 1.** OS and PFS estimates for 70 patients with hematologic diseases treated with RI-UCBT.

Table 3. Causes of Death

	Patients (n = 70)	
	No.	(%)
<b>NRM</b>	<b>37</b>	<b>(53)</b>
Infection	19	(27)
GVHD	9	(12)
IP	4	(6)
TMA	3	(4)
Others	2	(3)
Relapse	13	(19)
<b>Total</b>	<b>50</b>	<b>(71)</b>

NRM indicates nonrelapse mortality; GVHD, graft-versus-host disease; IP, interstitial pneumonia; TMA, thrombotic microangiopathy.

sex mismatch, number of infused cells, number of infused CD34<sup>+</sup> cells, and cGVHD did not reach statistical significance.

In the Cox regression analyses, recipient's age equal to or older than 61 (hazard ratio [HR] = 3.33; 95% confidence interval [CI] = 1.39-7.14;  $P = .006$ ), high risk disease (HR = 3.33; 95% CI = 1.01; 8.33  $P = .049$ ), grade III-IV aGVHD (HR = 2.5; 95% CI = 1.28; 5.88  $P = .0002$ ), and the presence of PIR (HR = 2.5; 95% CI = 1.14; 6.25  $P = .023$ ) were associated with statistically worse OS (Table 4). No other factors were significantly or suggestively associated with OS.

Regarding toxicity, multivariate analyses revealed that GVHD prophylaxis (HR = 3.9, 95% CI = 1.3-11.6 for CsA versus Tac;  $P = .01$ ) and aGVHD (HR = 5.7, 95% CI = 2.1-15.7 for grade III-IV versus 0-II;  $P = .001$ ) were associated with NRM.

## DISCUSSION

This study was undertaken to evaluate engraftment and toxicities in elderly patients with advanced hematologic diseases who received UCBT matched for at




Figure 2. NRM and disease progression. Cumulative incidence estimates of NRM and disease progression for all 70 patients.

least 4 loci of HLA-A, -B, and -DRB1 using a nonmyeloablative regimen.

Several observations were made. First and foremost, RI-UCBT was a feasible treatment strategy for elderly patients with a successful engraftment rate of 92% without secondary graft failure except disease progression. The average interval between transplant and neutrophil recovery to 500/ $\mu$ L was 18 days, which is comparable to previously reported in RIC [11,12]. The chimerism study confirmed rapid engraftment of donor cells in all engrafted patients. Together with the fact that all 3 evaluated patients who died before day 28 already achieved complete donor chimerism, these data indicate that our pretransplant conditioning regimens, mainly consisting of Flu, Mel, and TBI, along with single calcineurin inhibitors for GVHD prophylaxis, can exert sufficient immunosuppressive effects that allow engraftment of CB cells. Compared to the conditioning regimen containing cyclophosphamide reported from Minnesota group [11], which allow mixed chimeric state especially for myeloid lineages during the early period of posttransplant, our conditioning is more powerful in eradicating host myeloid cells as well, which may have beneficial effect for rapid control of myeloid malignancies. The OS and PFS were estimated as both 23% at 2 years posttransplant, almost comparable to or slightly less than the data reported previously [15,16,26], which can be reasonably explained by higher age range and poor disease status before transplant in this study cohort, which can be further supported by the result of subgroup analysis indicating those with standard disease status showed much better outcome (Figure 3B).

UCBT has been associated with lower incidence of aGVHD, possibly because of the immunologic naivety of transplanted lymphocytes; however, this naivety raises a concern about whether transplanted cells will have sufficient antimalignant activity. Several reports indicate the *in vivo* antimalignancy effect of cord blood cells [27-30]. Cumulative incidence of disease progression at 2 years posttransplant in our series was 24%, which is comparable to those previously reported [15,16,26]. It plateaued later than 795 days, indicating that our RI-UCBT treatment protocol offered fairly good disease control.

The incidence of GVHD was higher than previous reports in RIC [11,12], and was almost comparable to those of BM transplants, PB cell transplants, or UCBT with conventional conditioning [8-10,31-36]. Because of the poor disease status of the majority of patients included in this study, GVHD prophylaxis was initially planned to be less intensive with single calcineurin inhibitors. Older patients' age [37] or high incidence of infectious complications, which possibly induced excessive inflammatory cytokine secretions, could have been relevant to this result [38].




Figure 3. OS estimates after RI-UCBT ( $n = 70$ ). (A) Effect of age. (B) Effect of disease status. (C) Effect of severity of aGVHD. (D) Effect of PIR.

Although RI-UCBT has been a feasible approach in terms of engraftment, a significant number of patients died from treatment-related complications. NRM was close to 3 times higher than mortality from relapse or disease progression, and most NRM occurred within 100 days posttransplant. Of 37 deaths because of NRM, 19 were from infection. Delayed engraftment relative to other stem cell sources such as BM or PB cells has been suggested to account for the higher rate of infectious complications after UCBT [32,39,40], but the time to engraftment in our series of patients was not delayed. Higher grade of aGVHD and the presence of PIR were found to be significantly associated with poor OS in multivariate analysis, indicating that immune-mediated events have strong impact on patients' outcome (Table 4). PIR is the syndrome observed in our setting of RI-UCBT. Although the mechanism behind PIR has not been investigated extensively yet, it is assumed to be reflecting allo-immune event, given our experience that more intensive GVHD prophylaxis with Tac had tendency to decrease the incidence of PIR. Moreover, development of PIR may have been suppressed in reported cases from other institutes that utilized additional agents to calcineurin inhibitors, such as methotrexate [10,19], antithymocyte globulin [31], or mycophenolate mofetil [16]. There has been a similar early immune reaction-like syndrome reported as "hyperacute GVHD" observed following BM or PBSC transplant, and responded poorly to corticosteroids compared to traditional aGVHD [41,42]. The incidence of PIR was higher than that of hyperacute GVHD, and further investigation on biologic mechanisms may help us define

PIR more precisely relative to other immune-mediated diagnosis and develop optimal treatment approach. The presence of PIR was shown to cause more NRM than the absence in univariate analysis ( $P = .02$ ), although it did not reach statistical significance in multivariate analysis. Thus, better management of immune-mediated complications will be the key to reduce NRM and improve OS. Based on our early experience of high early mortality related to PIR in the patients with CsA prophylaxis, Tac was subsequently used to substitute for CsA, because Tac was shown to be more potent than CsA in BM transplant [43-45]. Patients who received Tac as GVHD prophylaxis had less chance of experiencing PIR compared with those who received CsA and had less NRM, indicating the potential benefit of using Tac as a standard agent for GVHD prophylaxis. Adding methotrexate, mycophenolate mofetil, or sirolimus to the calcineurin inhibitor may further improve the final outcome [10,11,46,47]. Older age was another factor that influenced OS with statistical significance, even within the age range studied (Figure 3A and Table 4). Patients aged 61 years and older experienced more NRM than patients younger than 61 years (65% versus 39%), whereas their death rate because of disease progression was comparable (19% versus 18%), suggesting the vulnerability of higher aged population to procedure toxicity. Although the possible impact of slight variation in conditioning regimen to the outcome cannot be excluded, it is unlikely, because the great majority (93%) were conditioned with Flu/Mel/TBI regimen fairly uniformly, and comparison between Flu/Mel/TBI and others did not reach statistical significance.

**Table 4.** Cox Regression Analyses of Factors Potentially Associated with OS and NRM after RI-UCBT

Variables	HR	95% CI	P
<b>OS</b>			
<b>Age</b>			
Less than 61 years (n = 33)	0.3	0.14-0.72	.006
At least 61 years (n = 37)	1.0		
<b>Disease risk</b>			
Standard (n = 15)	0.3	0.12-0.995	.049
High (n = 55)	1.0		
<b>PIR</b>			
No (n = 25)	0.4	0.16-0.88	.023
Yes (n = 43)	1.0		
<b>Acute GVHD</b>			
Grade 0-II (n = 31)	0.4	0.17-0.78	.0002
Grade III-IV (n = 23)	1.0		
<b>NRM</b>			
<b>GVHD prophylaxis</b>			
CsA (n = 37)	3.9	1.3-11.6	.01
Tac (n = 33)	1.0		
<b>Acute GVHD</b>			
Grade 0-II (n = 31)	1.0		
Grade III-IV (n = 43)	5.7	2.1-15.7	.001

GVHD indicates graft-versus-host disease; CsA, cyclosporine A; Tac, tacrolimus; NRM, nonrelapse mortality; CI, confidence interval; HR, hazard ratio; OS, overall survival.

In conclusion, this is the first study specifically focusing on elderly patients aged 55 years and older with advanced hematologic diseases to show the feasibility of RI-UCBT. Older age per se cannot be considered to be contraindication to RI-UCBT, although a high NRM has been observed. Further optimization of the treatment protocol, such as immunosuppressive therapy for GVHD prophylaxis, is warranted to establish the safety of this promising treatment strategy for elderly patients with advanced hematologic diseases.

#### ACKNOWLEDGMENTS

The authors wish to thank the data coordinators Kiku Morishita, Kaori Kobayashi, Sumiko Tanaka, and Naomi Yamada for their invaluable help in making this study possible. The authors also wish to thank all physicians, nurses, pharmacists, and support personnel for their care of patients in this study.

#### REFERENCES

- Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer*. 2006;107:2099-2107.
- Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. *JAMA*. 1993;270:57-60.
- Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. *Blood*. 2001;97:631-637.
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*. 2001;97:3390-3400.
- Slavin S, Nagler A, Nappastek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood*. 1998;91:756-763.
- Brunstein CG, Wagner JE. Cord blood transplantation for adults. *Vox Sang*. 2006;91:195-205.
- Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. *Bone Marrow Transplant*. 2006;38:83-93.
- Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Engl J Med*. 2004;351:2265-2275.
- Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med*. 2004;351:2276-2285.
- Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation of adult patients with hematologic malignancies. *Blood*. 2004;104:3813-3820.
- Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. *Blood*. 2003;102:1915-1919.
- Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. *Clin Cancer Res*. 2004;10:3586-3592.
- Koh LP, Chao NJ. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. *Biol Blood Marrow Transplant*. 2004;10:1-22.
- Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. *Ann Hematol*. 2006;86:49-54.
- Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. *Biol Blood Marrow Transplant*. 2007;13:82-89.
- Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. *Blood*. 2007;110:3064-3070.
- Narimatsu H, Matsumura T, Kami M, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. *Biol Blood Marrow Transplant*. 2005;11:429-436.
- Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. *Transplantation*. 2005;80:34-40.
- Narimatsu H, Terakura S, Matsuo K, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. *Bone Marrow Transplant*. 2007;39:31-39.
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106:2912-2919.
- Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, editors. *Hematopoietic Cell Transplantation*, 4th ed. Boston, MA: Blackwell Science; 1999. p. 515-536.

22. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis*. 2002;34:7-14.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.
24. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18:695-706.
25. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. *Ann Statist*. 1988;16:1141-1154.
26. Rocha V, Rio B, Brunstein C, et al. Unrelated cord blood transplantation after reduced intensity conditioning (RIC) in adults with hematological malignancy. An EBMT-Eurocord-Netcord, Société Française de Greffe de Moelle et de Therapie Cellulaire and University of Minnesota Collaborative study. *Blood*. 2007;110:603a.
27. Takami A, Takamatsu H, Yamazaki H, et al. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect. *Bone Marrow Transplant*. 2006;38:729-732.
28. Horey RP, Martin PL, Driscoll T, et al. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. *Bone Marrow Transplant*. 2000;26:1251-1254.
29. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. *Blood*. 2001;97:2962-2971.
30. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. *Blood*. 2002;100:1611-1617.
31. Sanz GF, Saavedra S, Planelles D, et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. *Blood*. 2001;98:2332-2338.
32. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. *Biol Blood Marrow Transplant*. 2003;9:772-780.
33. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). *Biol Blood Marrow Transplantation*. 2005;11:149-160.
34. Beatty PG, Cliff RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. *N Engl J Med*. 1985;313:765-771.
35. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. *Transplantation*. 1991;51:443-447.
36. Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). *Blood*. 2003;102:1541-1547.
37. Anasetti C, Beatty PB, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. *Hum Immunol*. 1990;29:79-91.
38. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. *Semin Hematol*. 2006;43:3-10.
39. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. *N Engl J Med*. 2001;344:1815-1822.
40. Ballen KK. New trends in umbilical cord blood transplantation. *Blood*. 2005;105:3786-3792.
41. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-versus-host disease in patients not given immunosuppression after allogeneic marrow transplantation. *Blood*. 1986;67:1172-1175.
42. Saliba RM, de Lima M, Giral S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. *Blood*. 2007;109:2751-2758.
43. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. *Bone Marrow Transplant*. 2001;28:181-185.
44. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood*. 1998;92:2303-2314.
45. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. *Blood*. 2000;96:2062-2068.
46. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. *Biol Blood Marrow Transplant*. 2004;10:246-258.
47. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. *Blood*. 2007;109:3108-3114.



## Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients: possible involvement of graft-versus-host disease

Eiji Kusumi · Masahiro Kami · Shigeo Hara · Junichi Hoshino · Yutaka Yamaguchi · Naoko Murashige · Yukiko Kishi · Yugo Shibagaki · Taro Shibata · Tomoko Matsumura · Koichiro Yuji · Kazuhiro Masuoka · Atsushi Wake · Shigesaburo Miyakoshi · Shuichi Taniguchi

Received: 28 August 2007 / Revised: 7 November 2007 / Accepted: 15 November 2007 / Published online: 9 February 2008  
© The Japanese Society of Hematology 2008

**Abstract** To investigate the association between graft-versus-host disease (GVHD) and renal injury after allogeneic stem cell transplantation (allo-SCT), we compared autopsy findings of 26 consecutive allo-SCT recipients with two control groups: patients with hematologic malignancies who received cytotoxic chemotherapy alone (Control 1,  $n = 21$ ) and those with non-hematologic diseases (Control 2,  $n = 12$ ). We evaluated the following renal pathology: renal tubulitis, allograft glomerulitis, intimal arteritis, allograft nephropathy, and peritubular capillaritis. These changes were found in 11 allo-SCT recipients and 10 patients in Control 1, but none in Control 2. While overall frequency of renal impairments was similar between allo-SCT recipients and Control 1 (3/26 vs. 1/21), allo-SCT recipients were more likely to have renal tubulitis and peritubular capillaritis compared to Control 1 (5/26 vs. 1/21), but less likely to present with glomerulitis (1/26 vs. 6/21). Grade III–IV acute or extensive-type

chronic GVHD were seen in all of the three patients with renal tubulitis and four of the five patients with peritubular capillaritis. Allo-SCT recipients with severe GVHD tended to have tubulitis and peritubular capillaritis. These findings have implications of some renal impairment attributable to GVHD.

**Keywords** Tubulitis · Capillaritis · Autopsy · Glomerulitis · Bone marrow transplantation

### 1 Introduction

Renal dysfunction is a common problem after allogeneic hematopoietic stem cell transplantation (allo-SCT) [1–3] and is associated with many factors. Patients may have preexisting renal injury from their underlying diseases or cytotoxic chemotherapy prior to allo-SCT. Preparative

E. Kusumi · T. Matsumura · K. Yuji · K. Masuoka · A. Wake · S. Miyakoshi · S. Taniguchi  
Department of Hematology, Toranomon Hospital, Tokyo, Japan

S. Hara  
Department of Pathology, Toranomon Hospital, Tokyo, Japan

J. Hoshino  
Kidney Center, Toranomon Hospital, Tokyo, Japan

E. Kusumi · M. Kami (✉) · T. Matsumura  
Division of Exploratory Research, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 1088639, Japan  
e-mail: kami-ky@umin.net

Y. Yamaguchi  
Department of Pathology, Jikei University Kashiwa Hospital, Chiba, Japan

N. Murashige  
Ministry of Health, Labour and Welfare,  
Office for Life-Style Related Diseases Control,  
Tokyo, Japan

Y. Kishi  
Division of Regenerative Medicine,  
Jichi Medical School, Tochigi, Japan

Y. Shibagaki  
Department of Nephrology, The Tokyo University Hospital,  
Tokyo, Japan

T. Shibata  
Statistics and Cancer Control Division,  
Research Center for Cancer Prevention and Screening,  
National Cancer Center, Tokyo, Japan

regimens before transplantation may directly cause renal damages. Post-transplant infections complicated by renal hypoperfusion sometimes lead to acute renal insufficiency. Antimicrobials used for prophylaxis and treatment of infections can be nephrotoxic.

Calcineurin-inhibitors (CNIs) are well known to cause renal dysfunction in allo-SCT recipients [4]. CNIs can lead to arteriolar hyalinosis, resulting in glomerular sclerosis [5, 6]. Chronic GVHD involving the kidney was reported in several case series [7, 8], while it is unclear whether there is an association between acute GVHD and renal damages [9]. Renal impairments are generally not considered a part of acute GVHD; however, *in vivo* imaging of GVHD in mice showed that several non-classical organs are massively infiltrated by cytotoxic T-cell (CTL) during GVHD, including the brain, the kidneys, and the connective tissues [10]. Infiltration of CTL into the kidney may explain the high response rates following allo-SCT for metastatic renal cell carcinoma [11], which derives from the proximal renal tubules.

Since allo-SCT recipients frequently suffer from thrombocytopenia and neutropenia, renal biopsy carries a considerable risk of hemorrhage and infections, although it is essential for making an accurate diagnosis of post-transplant renal dysfunction. Little is known about the pathology of renal injury following allo-SCT. To investigate the association between GVHD and renal injury after allo-SCT, we compared postmortem renal pathology of 26 consecutive allo-SCT recipients at Toranomon Hospital with two control groups: patients with hematologic malignancies who received cytotoxic chemotherapy alone and those with non-hematologic diseases.

## 2 Patients and methods

### 2.1 Patient and data collection

Of 284 patients with hematologic diseases who received allo-SCT at Toranomon Hospital between May 2000 and January 2005, 34 patients died and underwent autopsy. Eight patients with multiple myeloma were excluded from the study, since the primary disease can affect kidney [12]. The remaining 26 allo-SCT recipients were enrolled in the study (Case). The control groups comprised 21 consecutive patients with hematologic diseases other than multiple myeloma who underwent autopsy after repeated chemotherapy (Control 1), and 12 patients with non-hematologic diseases who were randomly selected from autopsy records (Control 2).

Complete clinical data were obtained from the autopsy request forms and the patients' records. Acute and chronic GVHD were assessed according to established criteria [13,

14]. Abnormal serum creatinine level was defined as 2.0 mg/dL and above. Clinical diagnosis of renal dysfunction was judged to be present by an experienced nephrologist (J.H.) based on the clinical presentation, laboratory results, and comorbid events such as sepsis, hypotension, and nephrotoxic drug exposure.

### 2.2 Renal pathology

Renal pathology was assessed based on the Banff 97 workshop [15] criteria by two independent renal pathologists (S.H. and Y.Y.) blinded to the clinical courses of patients enrolled in this study. Microscopic specimens stained with hematoxylin and eosin, periodic acid-Schiff, Masson trichrome, and silver methenamine were examined. Acute-type alloreaction consisted of tubulitis, interstitial infiltration of mononuclear cells, an early type of allograft glomerulitis, arterial hyaline thickening and intimal arteritis. Chronic-type alloreactions were allograft glomerulopathy, interstitial fibrosis, tubular atrophy and fibrous intimal thickening [15]. Interstitial damages such as mononuclear atrophy, interstitial fibrosis and tubular atrophy can be associated with conditions other than renal transplantation and were not included in the present study [16]. Arterial hyaline thickening may be caused by CNI and were also excluded from the analysis [6]. Thus, we investigated the following pathology of the Banff 97 workshop criteria [15]: renal tubulitis, allograft glomerulitis, intimal arteritis, allograft nephropathy.

An animal study showed that GVHD may target a vascular endothelium [17]. In renal transplantation, vascular involvement, which is focal process, reflects more severe rejection [15]. We therefore investigated the presence of peritubular capillaritis in this study.

### 2.3 Statistical analysis

A univariate analysis using Fisher's exact test and the Mann-Whitney test was performed to compare clinical features of renal damages between allo-SCT recipients and either Control 1 or Control 2 patients. The level of significance was set at  $P < 0.05$ .

## 3 Results

### 3.1 Patient characteristics

Patient characteristics are shown in Table 1. Allo-SCT recipients were significantly younger than Control 1 and Control 2 patients ( $P < 0.0001$  and  $P = 0.0005$ ,

**Table 1** Patient characteristics

Variables	Allo-SCT recipients (n = 26)	Control 1 <sup>a</sup> (n = 21)	Control 2 <sup>b</sup> (n = 12)
Age			
Median (range)	55 (16–70)	70 (54–93)	67 (59–93)
Sex			
Male/female	16/10	16/5	7/5
Primary disease			
Leukemia	16	10	0
Myelodysplastic syndrome	0	4	0
Malignant lymphoma	8	7	0
Solid tumors	1	0	8
Others	1	0	4
History of autologous stem cell transplant	6	1	0
Stem cell source			
Unrelated bone marrow	4		
Related bone marrow	3		
Related peripheral blood stem cell	6		
Unrelated cord blood	13		
Conditioning			
Myeloablative/reduced-intensity <sup>c</sup>	7/19		
GVHD prophylaxis			
Cyclosporine/tacrolimus	22/4		
GVHD			
Acute GVHD: grade 0–I/II–IV	18/8		
Chronic GVHD: none/limited/extensive <sup>d</sup>	5/2/4		
Abnormal serum creatinine level	12	8	2
Primary cause of death			
Disease progression	7	9	5
Infection	9	9	4
Interstitial pneumonitis	3	0	0
GVHD	5	0	0
Others	2	3	3

GVHD graft-versus-host disease

<sup>a</sup> Patients who received chemotherapy alone for the treatment of hematologic malignancies

<sup>b</sup> Patients with non-hematologic diseases

<sup>c</sup> Myeloablative regimens comprised cyclophosphamide 120 mg/kg and either total body irradiation 12 Gy (n = 4) or busulfan 16 mg/kg (n = 2). Reduced-intensity regimens were fludarabine 150 mg/m<sup>2</sup> and either melphalan 140 mg/m<sup>2</sup> (n = 3) or 80 mg/m<sup>2</sup> (n = 12), busulfan 8 mg/kg (n = 4) or cyclophosphamide 120 mg/kg (n = 1). Total body irradiation 4 Gy was added to reduced-intensity transplantation using unrelated bone marrow (n = 3) or cord blood transplantation (n = 12)

<sup>d</sup> Eleven patients who survived longer than 100 days were evaluated for chronic GVHD

respectively). Twelve of 26 allo-SCT recipients developed acute (n = 8) or chronic (n = 4) GVHD in their clinical courses, and GVHD was fatal in five.

### 3.2 Histological findings

Histopathological changes were found in 11 of the 26 allo-SCT recipients and 10 of the 21 Control 1 patients, while none in the 12 Control 2 patients (Table 2). The difference was statistically significant between allo-SCT recipients and Control 1 ( $P = 0.0075$ ), as well as between allo-SCT recipients and Control 2 ( $P = 0.0042$ ). While overall frequency of renal impairments was similar between allo-SCT recipients and Control 1 (Table 2), allo-SCT recipients were more likely to have renal tubulitis (Fig. 1) and peritubular capillaritis (Fig. 2) compared to Control 1. Allo-SCT recipients were less likely to develop glomerulitis


**Table 2** Histopathological findings

	Allo-SCT recipients (n = 26)	Control 1 (n = 21)	Control 2 (n = 12)
Total <sup>a</sup>	11	10	0
Renal tubulitis	3	1	0
Glomerulitis	1	6	0
Peritubular capillaritis	5	1	0
Intimal arteritis	0	0	0
Glomerulopathy	2	2	0

allo-SCT allogeneic hematopoietic stem cell transplantation

<sup>a</sup> Patients with any histopathological finding were counted

compared to Control 1. Four of the five patients with peritubular capillaritis and all of the three patients with renal tubulitis developed severe GVHD; grade II–IV acute GVHD or extensive chronic GVHD (Table 3).



**Fig. 1** Peritubular capillaritis: mononuclear leukocytes/neutrophil (arrowheads) within peritubular capillary (surrounded by dotted line)



**Fig. 2** Tubulitis: mononuclear leukocytes (arrowheads) infiltrating into renal tubular epithelium (surrounded by broken line)

**Table 3** Histological findings according to the severity of GVHD

	No GVHD (n = 13)	Mild GVHD (n = 1)	Severe GVHD (n = 12)
Renal tubulitis	0	0	3
Glomerulitis	0	0	1
Peritubular capillaritis	0	0	4
Intimal arteritis	0	0	0
Double contour	1	0	1

Mild GVHD: grade I acute GVHD or limited chronic GVHD; severe GVHD: grade II–IV acute GVHD or extensive chronic GVHD

#### 4 Discussion

Renal damage at autopsy was more frequently found in patients with hematologic malignancies compared to

subjects with non-hematologic diseases. Our results support the previous studies for hematologic diseases and all-SCT recipients [18, 19]. Since patients with hematologic malignancy receive higher dose of chemotherapy and more frequent infection during neutropenia compared to other neoplasms or benign conditions, renal dysfunction may be attributable to them as well as infiltration of underlying diseases.

Our study showed that all-SCT patients tend to develop more tubulitis and most of them had GVHD. A finding is consistent with earlier clinical and animal studies [9, 10], suggesting that tubules may be targeted in the GVHD. However, our finding showed lower rates of tubulitis compared to previous study reported by El-Seisi et al. (12 vs. 60%) [18]. This is likely due to the difference in diagnostic criteria of tubulitis. Patients who developed GVHD have higher rates of infection as well as antibiotic use and other medications. Degenerative changes, atrophy and necrosis of renal tubules can result from infection and medication use [20]. Therefore, atrophic and degenerative changes of the tubules are not considered tubulitis in the Banff criteria [15]. If we were to diagnose tubulitis based on degeneration, atrophy and necrosis of tubules, we would overestimate the effect of GVHD. The fact that 12% of all-SCT recipients had tubulitis using the strict criteria suggests the association between tubulitis and GVHD. In contrast, glomerulitis was more frequently observed in patients with hematologic disease without transplantation in this study. While its exact pathogenesis remains unknown, we can speculate some possibilities concerning it. First, patients with hematologic disease without transplantation tended to be old, and drugs such as anti-neoplastic, anti-bacterial, and anti-fungal agents might have injured their kidney [21, 22]. Second, glomerulitis sometimes develops in patients with hematologic diseases, since monoclonal gammaglobulinemia or cryoglobulinemia associated with hematologic diseases cause immune-mediated glomerulitis [23, 24]. It usually disappears with the remission of the underlying diseases. The primary disease is usually controlled in transplanted patients; therefore, glomerulitis might have disappeared in transplanted patients. Since hematologic diseases are rarely cured with chemotherapy alone in elderly patients, kidney injury might have persisted until autopsy in these patients.

Vascular changes in glomeruli are important components of Banff criteria [15]. A recent study indicated that C4d deposit in peritubular capillary is a part of humoral rejection [25]. The relationship between GVHD and intravascular damages was not reported in the previous studies [26, 27]. Our results revealed that all-SCT recipients had higher rates of peritubular capillaritis, but similar frequency of glomerulitis compared to the control groups.

Peritubular capillaritis was more frequently seen in severe GVHD. These results indicated the association between peritubular capillaritis and GVHD, and are consistent with the previous animal studies [28]. However, it remains unclear whether peritubular capillaritis results from GVHD, or from medications and infection, and further investigation is required. Lower rates of glomerulitis in bone marrow recipients compared to renal transplants may be due to differences of patients' characteristics between these two groups. Subjects who received renal transplants may tend to develop glomerulitis after transplants because of their primary diseases including glomerulonephritis [29, 30].

Our study suggests that kidney can be a target of GVHD and that Banff criterion is a useful tool to access renal pathology after allo-SCT. We believed that our finding will be helpful to clinicians, but there are several limitations to be discussed. First, the study was retrospective and small in size. Second, autopsy findings may not show active changes due to suppressed immune system postmortem. However, routine follow-up renal biopsy after renal transplants is not realistically plausible. In order to evaluate microscopic changes, we could only use autopsy pathology. Future study would understand this limitation and examine more autopsy cases to assess the association between GVHD and renal damages.

## References

- Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Figuera A, Motellon JL, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. *Am J Nephrol*. 1995;15(6):473-9.
- Imai H, Oyama Y, Miura AB, Endoh M, Sakai H. Hematopoietic cell transplantation-related nephropathy in Japan. *Am J Kidney Dis*. 2000;36(3):474-80.
- Zager RA. Acute renal failure in the setting of bone marrow transplantation. *Kidney Int*. 1994;46(5):1443-58.
- Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. *Transplantation*. 1985;40(3):249-53.
- Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. *Transplantation*. 2000;69 Suppl 12:SS11-3.
- Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. *Transplantation*. 2004;78(4):557-65.
- Kimura S, Horie A, Hiki Y, Yamamoto C, Suzuki S, Kuroda J, et al. Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma. *Blood*. 2003;101(10):4219-21.
- Suehiro T, Masutani K, Yokoyama M, Tokumoto M, Tsuruya K, Fukuda K, et al. Diffuse proliferative glomerulonephritis after bone marrow transplantation. *Clin Nephrol*. 2002;58(3):231-7.
- Homma CI, Kami M, Masuo S, Sakiyama M, Kojima R, Hori A, et al. Graft-versus-host disease of the kidney after rapid tapering of cyclosporin following reduced intensity hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2005;35(9):929-30.
- Panoskalis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody IS, et al. In vivo imaging of graft-versus-host-disease in mice. *Blood*. 2004;103(9):3590-8.
- Childs R, Chernoff A, Contentin N, Bahceci E, Schrupp D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med*. 2000;343(11):750-8.
- Kyle RA. Monoclonal proteins and renal disease. *Annu Rev Med*. 1994;45:71-7.
- Przeplorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. *Bone Marrow Transplant*. 1995;15(6):825-8.
- Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. *Semin Hematol*. 1991;28(3):250-9.
- Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int*. 1999;55(2):713-23.
- Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. *N Engl J Med*. 1998;339(20):1448-56.
- Ertault-Daneshpouy M, Leboeuf C, Lemann M, Bouhidel F, Ades L, Gluckman E, et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. *Blood*. 2004;103(12):4681-4.
- El-Seisi S, Gupta R, Clase CM, Forrest DL, Milanovic M, Couhan S. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2003;9(11):683-8.
- Harris KP, Hattersley JM, Feehally J, Walls J. Acute renal failure associated with haematological malignancies: a review of 10 years experience. *Eur J Haematol*. 1991;47(2):119-22.
- Thadhani R, Pascual M, Bonventre JV. Acute renal failure. *N Engl J Med*. 1996;334(22):1448-60.
- Perazella MA. Drug-induced nephropathy: an update. *Expert Opin Drug Saf*. 2005;4(4):689-706.
- Shankel SW, Johnson DC, Clark PS, Shankel TL, O'Neil WM Jr. Acute renal failure and glomerulopathy caused by nonsteroidal anti-inflammatory drugs. *Arch Intern Med*. 1992;152(5):986-90.
- Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. *Nephrol Dial Transplant*. 1998;13(6):1438-45.
- Moulin B, Ronco PM, Mougnot B, Francois A, Fillastre JP, Mignon F. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. *Kidney Int*. 1992;42(1):127-35.
- Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. *Am J Transplant*. 2003;3(6):708-14.
- Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. *Lancet*. 2002;359(9323):2078-83.
- Dumler JS, Beschoner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW. Endothelial-cell injury in cutaneous acute graft-versus-host disease. *Am J Pathol*. 1989;135(6):1097-103.

28. Shimizu A, Meehan SM, Kozłowski T, Sablinski T, Ierino FL, Cooper DK, et al. Acute humoral xenograft rejection: destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts. *Lab Invest.* 2000;80(6):815–30.
29. Braun MC, Stablein DM, Hamiwka LA, Bell L, Bartosh SM, Strife CF. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. *J Am Soc Nephrol.* 2005;16(7):2225–33.
30. Floege J. Recurrent IgA nephropathy after renal transplantation. *Semin Nephrol.* 2004;24(3):287–91.



## Unrelated Cord Blood Transplantation for Severe Aplastic Anemia

Ayami Yoshimi,<sup>1</sup> Seiji Kojima,<sup>2</sup> Shuichi Taniguchi,<sup>3</sup> Junichi Hara,<sup>4</sup> Toshimitsu Matsui,<sup>5</sup>  
Yoshiyuki Takahashi,<sup>2</sup> Hiroshi Azuma,<sup>6</sup> Koji Kato,<sup>7</sup> Tokiko Nagamura-Inoue,<sup>8</sup> Shunro Kai,<sup>9</sup>  
Shunichi Kato<sup>10</sup>

<sup>1</sup>Department of HSCT Data Management, Nagoya University, School of Medicine, Nagoya, Japan; <sup>2</sup>Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; <sup>3</sup>Department of Hematology, Toranomon Hospital, Tokyo, Japan; <sup>4</sup>Hematology/Oncology Department of Pediatrics, Osaka General Medical Center, Osaka, Japan; <sup>5</sup>Hematology/Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; <sup>6</sup>Hokkaido Cord Blood Bank, Sapporo, Japan; <sup>7</sup>Tokai Cord Blood Bank, Nagoya, Japan; <sup>8</sup>Tokyo Cord Blood Bank, Tokyo, Japan; <sup>9</sup>Hyogo Cord Blood Bank, Nishinomiya, Japan; and <sup>10</sup>Tokai University Cord Blood Bank, Isehara, Japan; on behalf of the Japan Cord Blood Bank Network (JCBBN)

Correspondence and reprint requests to: Seiji Kojima, MD, Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan (e-mail: kojimas@med.nagoya-u.ac.jp).

Received April 30, 2008; accepted July 2, 2008

### ABSTRACT

In the present study we evaluated the feasibility of unrelated cord blood transplantation (UCBT) in patients with severe aplastic anemia (SAA). The outcome of 31 SAA patients (median age 28; range: 0.9-72.3 years old) who received UCBT was analyzed. The cumulative incidences of the neutrophil and platelet recovery after UCBT were 54.8 and 72.2%, respectively (95% confidence interval [CI] = 36.0%-70.3% and 51.3%-85.3%, respectively). The cumulative incidences of grade  $\geq$ II acute and chronic graft-versus-host disease (aGVHD, cGVHD) were 17.1% (95% CI = 6.2%-32.8%) and 19.7% (95% CI = 6.2%-38.8%), respectively. Currently, 13 patients are alive, having survived for 33.7 months (median; range: 6-77 months) after UCBT. The probability of overall survival (OS) at 2 years was 41.1% (95% CI = 23.8%-57.7%). A conditioning regimen that included low-dose total body irradiation (TBI) (2-5 Gy), fludarabine, and cyclophosphamide resulted in a favorable OS (80%; 95% CI = 20.4%-96.9%). This result suggests that UCBT using the optimal conditioning regimen can be a salvage treatment for patients without a suitable bone marrow donor and warrants evaluation in further prospective studies.

© 2008 American Society for Blood and Marrow Transplantation

### KEY WORDS

Unrelated cord blood transplantation • Severe aplastic anemia

### INTRODUCTION

Over the last 2 decades, the outcome of patients with severe aplastic anemia (SAA) has dramatically improved regardless of whether patients received immunosuppressive therapy (IST) or bone marrow transplantation (BMT) [1-3]. BMT from an HLA-matched sibling is curative in the majority of younger patients with SAA, and is currently recommended as first-line treatment [4]. IST, with a combination of antithymocyte globulin (ATG) and cyclosporine (CSA), has been an alternative therapy for patients without an HLA-matched sibling. BMT from an unrelated donor (UD) is used as a salvage therapy for patients who fail

to respond to IST or who experience a relapse of the disease. However, in general, the results of UD-BMT have been inferior to those achieved with an HLA-matched sibling.

The report the Center for International Blood and Marrow Transplant Research (CIBMTR) on UD-BMT ( $n = 231$ ), for the period 1988-1998, showed that the overall survival (OS) rates for matched and mismatched UD-BMT in patients with SAA were 39% and 36%, respectively [5]. The Japan Marrow Donor Program (JMDP) reported a favorable outcome with 56% survival rate in 154 patients with SAA who received UD-BMT between 1993 and 2000 [6]. In

the recent 2 reports from the European Group for Blood and Marrow Transplantation (EBMT) and the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), the outcomes of UD-BMT for SAA before and after 1998 were compared. The results demonstrated improved OS rates of UD-BMT since year 1998 (32% versus 57% for EBMT and 29% versus 50% for SFGM-TC) [7,8]. The authors speculated that the better HLA matching because of the introduction of high-resolution HLA typing may have contributed to the improved outcomes. In pediatric series, 90% OS rates have been recently reported for UD-BMT patients, which is comparable to that observed for BMT from a matched sibling [9,10].

Treatment approaches for patients who lack a suitable unrelated bone marrow donor remain a great challenge. Cord blood has been used as an alternative source of HSCT, and it has the advantages of rapid availability on demand and a low incidence of graft-versus-host disease (GVHD). There were only a few reports on unrelated cord blood transplantation (UCBT), which included patients with SAA. The results showed poor outcome and high incidence of graft failure [11,12]. However, a few small series and case reports of successful UCBT for SAA have recently been reported [13-17]. Because of the possible reporting bias, the general efficacy of UCBT is still unknown. Therefore, we decided to further examine this procedure by using the database of the Japan Cord Blood Bank Network (JCBBN). We identified 31 patients with acquired SAA who received UCBT and analyzed the outcome.

## PATIENTS AND METHODS

### Patients

From September 1998 until February 2006, 53 patients with acquired SAA received UCBT through JCBBN. Twenty-two patients who received UCBT as a salvage therapy for the engraftment failure after previous HSCT were excluded, and the remaining 31 patients were included in this study. Patient characteristics and the cord blood units are summarized in Table 1. Patients were eligible for UCBT if they had no HLA-identical related or unrelated bone marrow donor. Patients who could not wait for UD-BMT because of unstable diseases were also considered to be eligible for UCBT. Cord blood units with 0 to 2 HLA locus mismatches by serology in HLA-A, HLA-B, and HLA-DRB1 were searched and then the unit with the largest cell dose was selected. At least  $2.0 \times 10^7$ /kg mononuclear cells (MNCs) were given in all patients.

The age of the patients ranged 0.9 to 72.7 years (median 27.9 years), and there were 8 patients older than 50 years of age. There were 25 patients who

Table 1. Patient and Donor Characteristics (n = 31)

Characteristic	
Median patient age, years (range)	27.9 (0.8-72.7)
Sex (male/female)	
Patient (n)	11/20
Donor (n)	14/17
Etiology of aplastic anemia	
Idiopathic/hepatitis associated (n)	30/1
Disease duration before UCBT: median, days (range)	337 (31-5063)
1 year or less/ 1-3 year/3 year or more/unknown (n)	13/4/8/5
Red blood cell transfusions before UCBT	
Less than 20 times/20 or more times/unknown (n)	8/21/2
Platelet transfusions before UCBT	
Less than 20 times/20 or more times/unknown (n)	7/22/2
HLA mismatches (serologic): GVHD direction (n = 31)	
0/1/2 (n)	4/18/9
HLA mismatches (serologic): rejection direction (n = 31)	
0/1/2 (n)	6/17/8
HLA mismatches (DNA typing): GVHD direction (n = 22)	
0/1/2/3/4 (n)	2/6/6/6/2
HLA mismatches (DNA typing): rejection direction (n = 22)	
0/1/2/3/4 (n)	1/5/12/3/1

UCBT indicates unrelated cord blood transplantation; GVHD, graft-versus-host disease.

had been previously treated with IST, including ATG + CSA (n = 13), ATG only (n = 4), or CSA only (n = 8). In 4 patients, androgen had been given. The remaining 2 patients were given only supportive therapy. All patients or their guardians gave informed consent for transplantation and submission of the data to the JCBBN.

### Recipient-Donor HLA Matching

Data were available for 31 patients with serology-based recipient-donor HLA matching and for 22 patients who underwent high-resolution DNA typing for class I-HLA-A, HLA-B, and DRB1 (Table 1). The HLA disparities for both GVHD and rejection directions are shown in Table 1.

### Transplantation Procedure

Characteristics of the transplantation procedures are listed in Table 2. The conditioning regimens varied according to the individual centers used. The 3 most commonly used regimens were: TBI (4-5 Gy) + fludarabine (FLU; 120-175 mg/m<sup>2</sup>) + Melphalan (MEL) (80-120 mg/m<sup>2</sup>) (n = 12), TBI (2-4 Gy) + FLU (90-250 mg/m<sup>2</sup>) and cyclophosphamide (CY; 50-100 mg/kg or 2250 mg/m<sup>2</sup>) (n = 5), and TBI (10-12 Gy) + CY (120-200 mg/kg) + ATG (n = 3). Of the 25 patients given irradiation, 24 received TBI



Table 2. Transplant Procedures (n = 31)

	No. of Patients
<b>Conditioning Regimen</b>	
TBI (4-5 Gy) + MEL + FLU	12
TBI (2-4 Gy) + CY + FLU	5
TBI (10-12 Gy) + CY + ATG	3
Others	11
<b>Radiation</b>	
TBI/TAI	25/1
No radiation	7
<b>ATG</b>	
Yes/No	7/24
<b>GVHD prophylaxis</b>	
CSA	6
CSA + others (MTX/steroid/MMF)	10
Tacrolimus	7
Tacrolimus + others (MTX/steroid)	8
<b>MNC cell dose</b>	
$\geq 2.0 \times 10^7/\text{kg}$ , $< 3.0 \times 10^7/\text{kg}$	15
$\geq 3.0 \times 10^7/\text{kg}$	16
<b>CFU-GM cell dose</b>	
$< 2.0 \times 10^4/\text{kg}$	14
$\geq 2.0 \times 10^4/\text{kg}$	15
Unknown	2
<b>CD34 cell dose</b>	
$< 1.0 \times 10^5/\text{kg}$	10
$\geq 1.0 \times 10^5/\text{kg}$	15
Unknown	6

TBI indicates total body irradiation; TAI, thoracoabdominal irradiation; MEL, melphalan; FLU, fludarabine; CY, cyclophosphamide; ATG, antithymocyte globulin; CSA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; MNC, mononuclear cell; CFU-GM, colony-forming unit granulocyte-macrophage.

and 1 underwent thoracoabdominal irradiation. A total of 7 patients were administered with ATG, either horse ATG (Lymphoglobulin 30-75 mg/kg in 5 patients) or rabbit ATG (Thymoglobulin 10 mg/kg in 2 patients). GVHD prophylaxis also varied according to the individual centers (Table 2). To facilitate the recovery of neutrophils, all patients received recombinant human granulocyte colony-stimulating factor. The number of mononucleated cells, colony-forming units of granulocyte-macrophage (CFU-GM), and CD34-positive cells of the cord blood units at the time of freezing are shown in Table 2.

#### Definitions and Statistical Analysis

The status of all patients was evaluated based on the last follow-up report, which was performed using the standardized forms provided by the JCBBN. All results were analyzed as of June 2008.

Date of engraftment was defined as the first of the 3 consecutive days where the neutrophil recovery was  $>0.5 \times 10^9/\text{L}$ . Platelet recovery was defined as the first of the 3 consecutive days where the unsupported platelet count was  $>50 \times 10^9/\text{L}$ . Chimerism was evaluated in 12 patients, with fluorescent in situ hybridization for the Y chromosome performed in 6 sex-mismatched grafts and quantitative polymerase chain reaction anal-

ysis for microsatellite DNA markers performed in 6 sex-matched transplantations. Acute and chronic GVHD (aGVHD, cGVHD) were diagnosed and graded according to standard clinical criteria [18,19].


Probability of OS was estimated according to the Kaplan-Meier method. GVHD and engraftment were assessed using the cumulative incidence procedure, and death was the competing event. Univariate comparisons among various groups were made using the log-rank test. The variables evaluated included age of the patient, donor sex, sex mismatch, disease duration before UCBT, the number of pre-UCBT transfusions for red cells and platelets, IST before UCBT, HLA matching by serology and high-resolution DNA typing for both GVHD and rejection directions, the number of mononuclear cells, CFU-GM, CD34-positive cells of the cord blood units at the time of freezing, conditioning regimens, and the administration of ATG and GVHD prophylaxis (single agent versus  $\geq 2$  agents, MTX versus no MTX, or CSA versus tacrolimus). All statistical analyses were carried out with version 10 of the STATA software (StataCorp, College Station, TX).

## RESULTS

### Engraftment

Sustained engraftment was observed in 17 patients. The cumulative incidences of the neutrophil and platelet recovery after UCBT were 54.8 and 72.2%, respectively (95% confidence interval [CI] = 36.0%-70.3% and 51.3%-85.3%, respectively; Figure 1). The median times to achieve a neutrophil count  $\geq 0.5 \times 10^9/\text{L}$  and a platelet count  $\geq 50 \times 10^9/\text{L}$  were 19 days (range: 12-35 days) and 59 days (range: 39-145 days), respectively. Chimerism analysis results were available in 8 patients with sustained neutrophil engraftment. All of these patients showed complete donor chimerism with more than 99% donor cells. No mixed chimerism was observed. There were 7 patients who failed to achieve sustained engraftment among patients who survived more than 28 days after UCBT. Five patients did not achieve a primary engraftment. Although 3 of them underwent a second UCBT, all died of infections, with (n = 1) or without (n = 2) engraftment of the second graft. Autologous recovery was noted in 1 patient, which was proven by the chimerism analysis that demonstrated 100% recipient cells. One patient had achieved engraftment on day 19, but she suffered from late graft failure at day 176 and received second HSCT at day 203. The patient was still alive at the time of the last follow-up.

Results of the univariate analysis for engraftment are shown in Table 3. The GVHD prophylaxis with a single agent (CSA or tacrolimus) exhibited a significantly better engraftment rate than that seen for the other methods (75.0% versus 33.3%,  $P = 0.02$ ).



**Figure 1.** (A) Cumulative incidence of sustained donor neutrophil engraftment ( $>0.5 \times 10^9/L$ ) and (B) platelet engraftment ( $>50 \times 10^9/L$ ) after unrelated cord blood transplantation in patients with aplastic anemia.

When there was a lower number of transfusions ( $<20$  times) of red cells and platelets prior to the HSCT, there was a trend for a better chance of successful engraftment compared to cases where there were higher

number of transfusions ( $\geq 20$  times), although this was not statistically significant. The number of infused MNCs, CFU-GM, and CD34 had no impact on the engraftment.

**Table 3.** Outcome following Unrelated Cord Blood Transplantations for Aplastic Anemia: Univariate Analysis

Covariates	2-Year-OS (%) (95% CI)	P	Engraftment (%) (95% CI)	P
<b>Recipient age</b>				
<20 year (n = 9)	44.4 (13.6-71.9)	.18	44.4 (13.6-71.9)	.76
20-40 year (n = 12)	56.3 (24.4-79.1)		66.7 (33.7-86.0)	
>40 year (n = 10)	20.0 (3.0-47.5)		50.0 (18.4-75.3)	
<b>Disease duration before UCBT</b>				
<1 year (n = 13)	35.7 (13.0-59.4)	.34	57.1 (28.4-78.0)	.67
$\geq 1$ year (n = 12)	47.6 (18.2-72.4)		58.3 (27.0-80.1)	
<b>RBC transfusions before UCBT</b>				
<20 (n = 8)	62.5 (22.9-86.1)	.26	75.0 (31.5-93.1)	.08
$\geq 20$ (n = 21)	31.4 (13.1-51.7)		47.6 (25.7-66.7)	
<b>Platelet transfusions before UCBT</b>				
<20 (n = 7)	57.1 (17.2-83.7)	.28	85.7 (33.4-97.9)	.05
$\geq 20$ (n = 22)	35.0 (16.1-54.7)		45.4 (24.4-64.3)	
<b>HLA matching by serologic typing (GVHD direction)</b>				
0-1 mismatched (n = 22)	49.2 (27.3-68.0)	.34	63.6 (40.3-79.9)	.10
2 mismatched (n = 9)	22.2 (3.4-51.3)		33.3 (78.3-62.3)	
<b>HLA matching by serologic typing (Rejection direction)</b>				
0-1 mismatched (n = 23)	43.5 (23.3-62.1)	.64	52.2 (30.5-70.0)	.59
2 mismatched (n = 8)	37.5 (8.7-67.4)		62.5 (22.9-86.1)	
<b>Conditioning regimen</b>				
TBI + CY + FLU (n = 5)	80.0 (20.4-96.9)	.02	75.0 (40.8-91.2)	.17
TBI + MEL + FLU (n = 12)	46.9 (17.6-71.9)		80.0 (20.4-96.9)	
Others (n = 14)	21.4 (5.2-44.8)		28.6 (08.8-52.4)	
<b>ATG</b>				
No (n = 24)	48.9 (27.8-67.0)	.007	66.7 (44.3-81.7)	.19
Yes (n = 7)	14.3 (0.7-46.5)		14.3 (0.7-46.5)	
<b>GVHD prophylaxis</b>				
CSA or tacrolimus only (n = 13)	54.6 (27.4-75.3)	.07	75.0 (46.3-89.8)	.02
CSA or tacrolimus+others (n = 18)	26.7 (8.3-49.6)		33.3 (12.2-56.4)	
<b>MTX</b>				
No (n = 20)	38.5 (17.7-59.1)	.93	60.0 (35.7-77.6)	.24
Yes (n = 11)	45.5 (16.7-70.7)		45.5 (16.7-70.7)	
<b>MNC</b>				
$2 \times 10^7/kg$ - $3 \times 10^7/kg$ (n = 15)	45.0 (19.4-67.8)	.61	60.0 (31.8-79.7)	.70
$\geq 3 \times 10^7/kg$ (n = 15)	37.5 (15.4-59.8)		50.0 (24.-71.0)	
<b>CD34</b>				
$<1 \times 10^5/kg$ (n = 15)	45.7 (14.3-73.0)	.32	70.0 (32.9-89.2)	.52
$\geq 1 \times 10^5/kg$ (n = 15)	33.3 (12.2-56.4)		53.3 (26.3-74.4)	

GVHD indicates graft-versus-host disease; TBI, total-body irradiation; CY, cyclophosphamide; Mel, melpharan; Flu, fludarabine; ATG, antithymocyte globulin; CSA, cyclosporine; MTX, methotrexate; MNC, mononuclear cell; CFU-GM, colony-forming unit-granulocyte macrophage; UCBT, unrelated cord blood transplantation.

### GVHD and Viral Infections

Acute GVHD ( $\geq$  grade II) was observed in 5 patients (grade II;  $n = 4$ , grade III;  $n = 1$ ) on days 8 through 56, and was lethal in the 1 patient with grade III aGVHD. Chronic GVHD was observed in 4 patients (extensive:  $n = 1$ , limited:  $n = 3$ ; de novo  $n = 2$ , progression from aGVHD  $n = 2$ ) on days 124 through 213. Figure 2 depicts the cumulative incidence of grade II-IV aGVHD (17.1%; 95% CI = 6.2%-32.8%) and cGVHD (19.7%; 95% CI = 6.2%-38.8%). Viral reactivations were commonly observed in this study. CMV reactivation was noted in 9 patients, and 1 of them developed CMV disease. Epstein-Barr virus (EBV) reactivation was noted in 1 patient, having developed cerebral infarction, which was considered to be related with EBV. Adenovirus induced cystitis occurred in 1 patient.

### Survival

Of the 31 total patients, 13 are presently alive, with survival durations of 6 to 77 months (median 33.7 months) after the transplantations. The probability of OS at 2 years was 41.1% (95% CI = 23.8%-57.7%). The results of univariate analysis of the factors influencing survival are shown in Table 3. The conditioning regimen and the administration of ATG were the only factors that were significantly related to the survival. The conditioning regimen, which included low-dose TBI, FLU, and CY, resulted in better outcomes than were seen for the other regimens (Table 3 and Figure 3). The administration of ATG was associated with poor outcome (Table 3 and Figure 3). There were 5 out of 7 patients given ATG that died before engraftment because of infections ( $n = 3$ ) or hepatic veno-occlusive disease (VOD) ( $n = 2$ ). In the 2 other patients, 1 demonstrated autologous recovery, whereas the other patient has had sustained engraftment and is currently still alive. There tended to be a better outcome noted for GVHD prophylaxis with a single agent (either CSA or tacrolimus) compared to prophylaxis with 2 or more agents. The outcome for the patients aged 40 years and older was inferior to that seen for the younger patients, although this was not statistically significant.

In the 18 patients who died, the causes of death were graft failure ( $n = 7$ ), bacterial/fungal infections ( $n = 3$ ), EBV-related cerebral infarction ( $n = 1$ ), VOD ( $n = 3$ ), aGVHD ( $n = 1$ ), acute respiratory distress syndrome ( $n = 1$ ), encephalopathy ( $n = 1$ ), and cardiac toxicity ( $n = 1$ ).

### DISCUSSION

The outcome of 31 patients with SAA who received UCBT was analyzed in this study. This is the first report on a nationwide multicenter study that focused on UCBT for SAA as far as we know. The overall survival rate was 41%, which is comparative to the results of the large registry-based analysis of UD-BMT for SAA by CIBMTR [5], but inferior to the results of some recent reports of UD-BMT [6,20]. The incidence and the severity of aGVHD and cGVHD were considerably lower in this study, which is advantageous for UCBT. The major problem encountered, however, was still the high incidence of engraftment failure after UCBT. In the present study the conditioning regimen with the low-dose TBI, FLU, and CY resulted in better outcome (80% survival rate) compared to other regimens. This regimen and the selection of optimal donor with better HLA match and higher cell dose may improve the outcome of UCBT for SAA.

Previous reports on the conditioning regimen of UCBT for SAA are limited. Mao et al. [13] reported on 9 patients with SAA who were conditioned with ATG and CY (60 mg/kg) prior to undergoing UCBT. A total of 7 out of 9 of these patients survived with hematologic recovery. However, a donor-recipient mixed chimerism was present in all patients. There are a few case reports of UCBT for SAA using more intensified regimens, which resulted in successful engraftment along with complete chimerism [14-16,21].

Radiation-containing regimens are efficient in achieving better engraftments and widely used within the UD-BMT settings for patients with SAA; although these regimens are associated with significant early and late toxicities, including secondary malignancies [22]. Recent study by Deeg et al. [20] to define the optimal TBI dose in combination with CY (200 mg/kg) and





Figure 2. Cumulative incidence of  $\geq$  grade II aGVHD (A) and cGVHD (B) in patients with aplastic anemia who received UCBT.



**Figure 3.** Probability of survival after conditioning regimens in patients with aplastic anemia, who received unrelated cord blood transplantation. TBI: total body irradiation, CY: cyclophosphamide, MEL: melphalan, FLU: fludarabine, ATG: antithymocyte globulin.

ATG for use with UD-BMT in patients with SAA showed that 2 Gy was sufficient to allow engraftment without increasing toxicities. This finding was also supported by a Japanese study on UD-BMT in patients with SAA, which reported that in a small group given a conditioning regimen of low-dose TBI (2-5 Gy), CY (200 mg/kg), and ATG, there was a 90% survival rate [7].

Fludarabine is currently widely used for nonmyeloablative transplants for a variety of diseases including SAA [23-26]. In the recent study on UD-SCT from the Severe Aplastic Anemia Working Party of the EBMT (SAA WP-EBMT), they designed a non-TBI regimen that used FLU (120 mg/m<sup>2</sup>), CY (1200 mg/m<sup>2</sup>), and ATG [27]. In this study, a total of 38 both pediatric and adults patients with SAA were included (36 BMT and 2 PBSCT patients) and the 2-year survival rate was 73%, with a low incidence of aGVHD and cGVHD. Therefore, this result suggests that a FLU containing regimen might be effective for use with UD-HSCT in SAA. The authors suggested that the conditioning regimen might need to be modified for adults through the addition of a low dose of TBI, as there was a significantly lower engraftment rate seen in the adult patients (82% overall, 68% in adults). Overall, these findings in previous reports and in this study suggest that the conditioning regimen that included the low-dose TBI and FLU resulted in favorable outcomes. In present study, the 7 patients given ATG were poor. Only 1 of them achieved engraftment and is alive. However, the number of patients given ATG was too small to reach any definitive conclusions and the benefit of ATG in UCBT for SAA should be evaluated in a large prospective study.

The GVHD prophylaxis using a single agent (CSA or tacrolimus) exhibited a better engraftment rate and a marginally better survival rate compared to that seen when 2 or more immunosuppressive agents were used. In the latter group, steroid, MTX, or mycophenolate mofetil (MMF) were given in addition to CSA or tacrolimus. Because of the limited number of patients and the highly heterogeneous regimen of the GVHD prophylaxis in this study, it is difficult to define the optimal GVHD prophylaxis based on the current results.

However, the low incidence and severity of GVHD that we noted in our study suggests that a single agent, regardless of whether it is tacrolimus or CSA, may be effective enough to prevent GVHD in UCBT for SAA.

One of the most important factors that determine the success of UCBT is the cell dose in the CB [11,28-30]. In the present study, a minimum of  $2 \times 10^7$ /kg MNCs were infused in all patients. In this condition, the dose of MNCs, CFU-GM, and CD34 had no impact on engraftment and survival. One of the benefits of UCBT is that it can overcome the HLA barrier. Despite the HLA disparity in the majority of the patients, the incidence of GVHD was quite low in this study. There was a tendency for better HLA matching to result in a better outcome, although this was not statistically significant. Selection of the CB units with higher cell dose and better HLA match may be essential to improve the outcome of UCBT for SAA.

In our study there were also 8 patients who were older than 50 years of age, which is generally considered to be over than the cutoff age for transplantation. Because of the poor outcome of UCBT in older patients (OS = 20% in group with age >40 years old), UCBT cannot be recommended for older patients at present, and repeated IST should be considered in these patients [31,32].

In summary, this first multicenter study focused on the UCBT for SAA suggests that UCBT can be an alternative treatment for SAA patients who failed to IST and have no suitable bone marrow donor. The results may be improved by using the optimal conditioning regimen such as low-dose TBI, FLU, and CY and by donor selection of better HLA match and higher cell dose.

#### ACKNOWLEDGMENTS

This work was supported by a Research Grant for Tissue Engineering (H17-014) from the Japanese Ministry of Health, Labor, and Welfare. The authors would like to thank all of the staff members of the collaborating institutes of the Japan Cord Blood Bank Network for taking care of and reporting information on the patients. We would also like to thank Dr. Yoshiko Atsuta for the statistical analysis support.